Failed remyelination of the nonhuman primate optic nerve leads to axon degeneration,retinal damages,and visual dysfunction

White matter disorders of the central nervous system (CNS), such as multiple sclerosis (MS), lead to failure of nerve conduction and long-lasting neurological disabilities affecting a variety of sensory and motor systems, including vision. While most disease-modifying therapies target the immune and inflammatory response, the promotion of remyelination has become a new therapeutic avenue to prevent neuronal degeneration and promote recovery. Most of these strategies have been developed in short-lived rodent models of demyelination, which spontaneously repair and do not reflect the size, organization, and biology of the human CNS. Thus, well-defined nonhuman primate models are required to efficiently advance therapeutic approaches for patients. Here, we followed the consequence of long-term toxin-induced demyelination of the macaque optic nerve on remyelination and axon preservation, as well as its impact on visual functions. Findings from oculomotor behavior, ophthalmic examination, electrophysiology, and retinal imaging indicate visual impairment involving the optic nerve and retina. These visual dysfunctions fully correlated at the anatomical level, with sustained optic nerve demyelination, axonal degeneration, and alterations of the inner retinal layers. This nonhuman primate model of chronic optic nerve demyelination associated with axonal degeneration and visual dysfunction, recapitulates several key features of MS lesions and should be instrumental in providing the missing link to translate emerging repair promyelinating/neuroprotective therapies to the clinic for myelin disorders, such as MS.

White matter disorders are a large group of neurological diseases of various origins. Those affecting the central nervous system (CNS), such as multiple sclerosis (MS), lead to failure of nerve conduction, axon degeneration, and result in long-lasting neurological disabilities and tissue atrophy (1). The loss of myelin and healthy axons are believed to be responsible for irreversible damages, which affect a variety of sensory and motor systems, including vision. In MS, 70% of patients are affected with optic neuritis. It can manifest in an acute episode with decreased vision that can recover over several weeks in the majority of patients, while permanent visual symptoms persist in 40 to 60% of patients (2, 3). Chronic optic neuritis can lead to significant optic nerve atrophy and retinal alterations, affecting mainly the retinal inner layers, including the retinal nerve fiber and ganglion cell layers (4). Several visual assays, including visual fields (VF) (5), pupillary responses to luminance and color (pupillary light reflex, PLR) (6), electroretinograms (ERG) (7), optical coherence tomography (OCT) (4, 8), and visual evoked potential (VEP) (9–11) are routinely performed to assess noninvasively the anatomical and electrophysiological perturbations of visual functions in MS. While functional recovery was reported in some patients (9), the lack of anatomical–electrophysiological correlation has prevented to attribute directly these improvements to remyelination or other regenerative processes.Animal models of demyelination induced by toxins, such as lyso-phosphatidylcholine (LPC), are suitable for studying the mechanisms of demyelination/remyelination and developing approaches aimed at promoting CNS remyelination, as they show little inflammation and, therefore, provide means to assay directly the effect of a therapy on remyelination. However, most of these models are developed in short-lived rodents and spontaneously repair, thus lacking the long-lasting progressive degenerative disease context of MS. Besides, these models do not reflect the size or complex organization of the human primate CNS (12). They do not inform on the biology of primate cells, which differs from rodents (13, 14), nor on the security, toxicity, and long-term efficacy of cell- or compound-based promyelinating/neuroprotective therapies. Thus, experiments in long-lived nonhuman primates appear an essential step toward clinical trials.While promoting remyelination may prevent axon degeneration, only a few promyelination strategies have been translated to the clinic (15,16). One of the roadblocks is the absence of studies addressing the clinical benefit of promyelination approaches that could be applied to the clinic (17). A positive correlation between changes in VEP parameters and the degree of demyelination/remyelination was established in rodents (18–21), cats (22), and dogs (23), and exploited successfully to follow promyelination therapies in rodents (24, 25). OCT has been used to identify loss of optic nerve and retinal damages in animal models of myelin disorders as well (23, 26). While used seldomly in nonhuman primates (27), none of these clinical assays were exploited to monitor the impact of optic nerve demyelination in nonhuman primates.We previously demonstrated that LPC injection in the macaque optic nerve induced demyelination with fair axon preservation but little remyelination up to 2 mo post demyelination (28). Taking advantage of the fact that nonhuman primates are long-lived and are able to perform several tasks awake, as do humans, we questioned whether this model could be used to follow the consequence of long-term demyelination on axon preservation, and whether multimodal noninvasive assays, such as VF, VEP, OCT, and PLR could be instrumental to follow/predict the functional and anatomical outcome of optic nerve demyelination. Using multidisciplinary approaches, we provide compelling evidence that LPC-induced demyelination of the macaque optic nerve leads to modified VF, VEP, PLR, and altered inner retinal layers, but preserved photoreceptors based on OCT and ERG. These clinical and functional anomalies were correlated at the histological level with failed remyelination and progressive optic nerve axon loss, followed by neuronal and fiber loss of the inner retinal layers. The postmortem validation of OCT, VEP, and PLR as pertinent markers of optic nerve demyelination/degeneration could further help the translation of therapeutic strategies toward the clinic for myelin diseases associated with long-term demyelination of the optic nerve.     

COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence

The liver is frequently affected by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. The most common manifestations are mildly elevated alanine aminotransferase and aspartate aminotransferase, with a prevalence of 16-53% among patients. Cases with severe coronavirus disease 2019 (COVID-19) seem to have higher rates of acute liver dysfunction, and the presence of abnormal liver tests at admission signifies a higher risk of severe disease during hospitalization. Patients with chronic liver diseases also have a higher risk of severe disease and mortality (mainly seen in patients with metabolic-associated fatty liver disease). Several pathways of damage have been proposed in the liver involvement of COVID-19 patients; although, the end-cause is most likely multifactorial. Abnormal liver tests have been attributed to the expression of angiotensin-converting enzyme 2 receptors in SARS-CoV-2 infection. This enzyme is expressed widely in cholangiocytes and less in hepatocytes. Other factors attributed to liver damage include drug-induced liver injury, uncontrolled release of proinflammatory molecules (“cytokine storm”), pneumonia-associated hypoxia, and direct damage by the infection. Hepatic steatosis, vascular thrombosis, fibrosis, and inflammatory features (including Kupffer cell hyperplasia) are the most common liver histopathological findings in deceased COVID-19 patients, suggesting important indirect mechanisms of liver damage. In this translational medicine-based narrative review, we summarize the current data on the possible indirect mechanisms involved in liver damage due to COVID-19, the histopathological findings, and the impact of these mechanisms in patients with chronic liver disease.     

缺血预处理程序中心肌环磷酸腺苷含量及环磷酸腺苷依赖蛋白激酶活性的变化

目的:制备大鼠在体缺血再灌注模型,观察缺血预处理程序中心肌环磷酸腺苷含量及环磷酸腺苷依赖蛋白激酶活性的变化。方法:实验于2005-03/2006-10在解放军沈阳军区总医院医学实验动物中心和全军心血管研究所实验室完成。实验分组:选用健康雌性SD大鼠36只,根据预适应程序分为第1,2,3次缺血,第1,2,3次再灌注,每一时间点6只大鼠。实验过程:用手术套管法造成左冠状动脉主干缺血及再灌注。所有实验动物在实验程序结束后,取出心脏迅速置液氮保存备用。实验评估:用放射免疫法测环磷酸腺苷水平,生化法测环磷酸腺苷依赖蛋白激酶活性变化。结果:36只大鼠均进入结果分析。①环磷酸腺苷含量:第1次再灌注组低于第1次缺血组[(0.325±0.015),(0.395±0.024)pmol/g,t=6.06,P<0.001],第2次再灌注组低于第2次缺血组[(0.523±0.017),(0.708±0.067)pmol/g,t=6.56,P<0.001],第3次再灌注组低于第3次缺血组[(0.567±0.031),(0.712±0.038)pmol/g,t=7.24,P<0.001]。②环磷酸腺苷依赖蛋白激酶活性:第1次再灌注组低于第1次缺血组[(10.115±1.000),(16.351±0.849)pkat/g,t=11.12,P<0.001],第2次再灌注组低于第2次缺血组[(11.877±2.213),(14.869±0.619)pkat/g,t=3.31,P<0.01],第3次再灌注组低于第3次缺血组[(11.745±0.987),(14.766±0.329)pkat/g,t=7.09,P<0.001]。③缺血预处理程序中心肌环磷酸腺苷含量及环磷酸腺苷依赖蛋白激酶活性随缺血及再灌注呈周期性波动。在5min缺血预处理时表现为明显增高,而在间隔的再灌注程序中恰呈相反改变,有明显下降的趋势。结论:环磷酸腺苷及环磷酸腺苷依赖蛋白激酶的周期性波动变化可能是激发心肌缺血预处理的机制之一,环磷酸腺苷可能在预处理保护作用中起一些作用。     

Prevalence and factors associated with anthropometric failure,vitamin A and iron deficiency among adolescents in a Nigerian urban community

BackgroundUnder nutrition is a problem of severe magnitude in low income countries like Nigeria. Adolescent school children might also be vulnerable. The dearth of data hinders planning of school health and nutrition programmes for school children.ObjectiveTo determine the prevalence of stunting, thinness; vitamin A and iron deficiencies among adolescent students in Nsukka urban, Nigeria and to determine factors that are associated with these nutritional problems.MethodsA total of 400 participants were randomly selected from 717 students aged 12 – 18 years in 3 randomly selected secondary schools. Questionnaires, anthropometric measurements, and blood analyses were the data collection methods employed.ResultsThe prevalence of stunting was 33.3% and thinness 31.0%. Neither overweight nor obesity was observed. While 64.0% were anaemic; 44.0% had vitamin A deficiency (VAD). A total of 48.0% had both anaemia and stunting, 42% had VAD + thinness; while 40% had anaemia + VAD. Household income was a predictor of vitamin A status. Children from medium/high income households had higher odds of having VAD than those from low income households (AOR=0.14; 95% CI=0.031, 0.607; P=0.009). Household income (AOR=0.12; 95% CI=0.021, 0.671; P=0.016), and age (AOR=0.09; 95% CI=0.014, 0.587; P=0.012) were independent determinants of height-for-age status.ConclusionAmong urban adolescent students in Nigeria, stunting, thinness, anaemia and VAD were problems of public health significance. Age and household monthly income played major roles.     

Balloon dilatation of critical stenosis of the pulmonary valve in neonates

Percutaneous balloon dilatation was attempted in 15 consecutive neonates (mean age 7.3 (range 1-27) days and weight 3.2 (range 2.5-4.1) kg) with critical stenosis of the pulmonary valve. Dilatation was successful in 11 (73%) patients. The mean balloon to annulus ratio was 1.1 (range 0.6-1.77). The ratio of right ventricle to femoral artery systolic pressure decreased from a mean (1 SD) of 1.4 (0.32) before to 0.8 (0.24) after dilatation and the transvalvar gradient decreased from 81 (29.7) mm Hg before to 33 (27.7) mm Hg after dilatation. All four (27%) patients in whom dilatation was unsuccessful underwent surgical valvotomy. Complications of balloon dilatation occurred in three (20%) patients; these included retroperitoneal haematoma (one) and iliofemoral venous occlusion (two). In one (7%) patient severe hypoxia and hypotension developed when the valve was crossed with a guide wire and balloon catheter. Despite successful dilatation he died 7 days after the procedure. During a mean (1 SD) follow up of 2 (1.7) years, seven (64%) of the 11 patients remained free of important restenosis. One patient required repeat dilatation three weeks after the initial procedure. In three (27%) patients restenosis developed 4-9 months after dilatation and all three had surgical valvotomy. Of the four patients initially referred for surgery three required a second operation and one required balloon dilatation. Percutaneous balloon dilatation gave effective relief of critical pulmonary stenosis in most neonates but complications and restenosis requiring surgery were common.